PMID- 17555885
OWN - NLM
STAT- MEDLINE
DCOM- 20080103
LR  - 20071030
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 69
IP  - 6
DP  - 2007
TI  - A novel vicious cycle cascade in tumor chemotherapy.
PG  - 1230-3
AB  - Dendritic cells (DCs) play a critical role in both the cellular and humoral 
      immune response to tumor cells. The participation of co-stimulator molecules on 
      DCs is of vital importance for full activation of T cells. Conventional tumor 
      chemotherapy cannot only induce apoptosis of malignant cells, but also do harm to 
      benign DCs. Expression levels of co-stimulatory molecules (especially CD80 and 
      CD86) are downregulated during anticancer drug treatment. These DCs are defective 
      in their antigen-presenting function being lack of sufficient co-stimulatory 
      molecules. Immune defective DCs provide negative immune signals to CD4+ and CD8+ 
      T cells. Thereby these T cells are induced to become tolerant to the tumor cells, 
      and function as T regulatory/suppressor cells to induce tolerogenic DCs by 
      cell-cell contact. These DCs tolerized to tumor antigens may further render 
      tolerogenicity to many more T cells via intercellular contact, and thus lead to a 
      vicious cycle cascade. This model allowed us to envisage modified strategies of 
      antitumor chemotherapy. We may use anticancer drugs with higher specificity to 
      tumor cells, or in combination with immunopotentiator to disrupt the vicious 
      cycle cascade, and expect better clinical result.
FAU - Zhou, Hao
AU  - Zhou H
AD  - Institute of Hematology, Union Hospital of Tongji Medical College, Huazhong 
      University of Science & Technology, 1277 Jiefang Road, Wuhan, Hubei 430022, 
      China.
FAU - Zou, Ping
AU  - Zou P
FAU - Chen, Zhi-Chao
AU  - Chen ZC
FAU - You, Yong
AU  - You Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070606
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antigen Presentation
MH  - Antineoplastic Agents/*adverse effects
MH  - Apoptosis
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Dendritic Cells/*drug effects
MH  - Humans
MH  - Immune System
MH  - Lymphocyte Activation
MH  - *Models, Immunological
MH  - Models, Theoretical
MH  - Neoplasms/*drug therapy/*immunology
EDAT- 2007/06/09 09:00
MHDA- 2008/01/04 09:00
CRDT- 2007/06/09 09:00
PHST- 2007/03/26 00:00 [received]
PHST- 2007/03/28 00:00 [accepted]
PHST- 2007/06/09 09:00 [pubmed]
PHST- 2008/01/04 09:00 [medline]
PHST- 2007/06/09 09:00 [entrez]
AID - S0306-9877(07)00286-1 [pii]
AID - 10.1016/j.mehy.2007.03.038 [doi]
PST - ppublish
SO  - Med Hypotheses. 2007;69(6):1230-3. doi: 10.1016/j.mehy.2007.03.038. Epub 2007 Jun 
      6.